NCT07653958 Risk Factor Assessment for Acute Pulmonary Hypertension Crisis
| NCT ID | NCT07653958 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Pulmonary Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2026-06-17 |
| Primary Completion | 2029-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2026-06-17 with a primary completion date of 2029-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about pulmonary hypertension crisis (PHC) - a severe, and often fatal complication - in patients with pulmonary hypertension (PH). The main questions this study aims to answer are: What are the clinical and hemodynamic features of PHC, and what underlying pathophysiological mechanisms cause it to develop? Can these features be used to diagnostic PHC, predict who is at risk of developing it or dying from it, and develop targeted prevention and treatment of PHC? A multi-center registry platform and biobank will be established to enroll and follow up patients with PH. Clinical data, hemodynamic measurements, and biological specimen will be collected. Risk prediction and early warning tools of PHC will be developed.
Eligibility Criteria
Inclusion Criteria: * Pulmonary hypertension confirmed by mean pulmonary arterial pressure (mPAP) over 20 mmHg measured by right heart catheter * At least once per year of follow-up data collection record Exclusion Criteria: * Patients with missing baseline or follow-up data * Complicated by other diseases with significant influence on survival, such as acute coronary syndrome, malignancy, etc. * Complicated by other diseases with significant influence on hemodynamics, such as sepsis, acute left heart failure, and acute pulmonary embolism, etc. * Receiving medications with significant influence on hemodynamics
Contact & Investigator
Jinmin Peng, MD
PRINCIPAL INVESTIGATOR
Peking Union Medical College Hospital
Frequently Asked Questions
Who can join the NCT07653958 clinical trial?
This trial is open to participants of all sexes, studying Pulmonary Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07653958 currently recruiting?
Yes, NCT07653958 is actively recruiting participants. Contact the research team at dongrun5858@foxmail.com for enrollment information.
Where is the NCT07653958 trial being conducted?
This trial is being conducted at Guangzhou, China, Kunming, China, Beijing, China, Shanghai, China.
Who is sponsoring the NCT07653958 clinical trial?
NCT07653958 is sponsored by Peking Union Medical College Hospital. The principal investigator is Jinmin Peng, MD at Peking Union Medical College Hospital. The trial plans to enroll 5,000 participants.